# A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

> **NCT02030275** · PHASE2 · COMPLETED · sponsor: **RXi Pharmaceuticals, Corp.** · enrollment: 25 (actual)

## Conditions studied

- Hypertrophic Scar

## Interventions

- **DRUG:** RXI-109
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02030275
- **Lead sponsor:** RXi Pharmaceuticals, Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02030275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02030275, "A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02030275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*